This inventor holds 1 USPTO granted patent. Top assignee: Ramot University Authority for Applied Research and Industrial Development Limited. Active years: 2002.
Company Filing History:
Years Active: 2002
Title: Rafael Bruck: Innovator in Non-Malignant Disease Treatment
Introduction
Rafael Bruck is a notable inventor based in Rishon Le-Zion, Israel. He has made significant contributions to the field of medical research, particularly in the treatment of non-malignant diseases. His innovative approach focuses on utilizing Ras antagonists to inhibit cell proliferation associated with various pathological conditions.
Latest Patents
Rafael Bruck holds a patent for a method of treating non-malignant diseases using Ras antagonists. The patent describes a method for inhibiting Ras-induced or mediated proliferation of cells linked to non-malignant diseases, disorders, or pathological conditions. This method involves administering a Ras antagonist in an effective amount to inhibit cell proliferation. The invention is particularly relevant for diseases characterized by T-cell proliferation, such as autoimmune diseases like type 1 diabetes, lupus, and multiple sclerosis. It also addresses pathological states like graft rejection and other conditions such as cirrhosis of the liver and restenosis. Preferred Ras antagonists include S-trans-trans farnesylthiosalicylic acid (FTS) and its structurally related compounds.
Career Highlights
Rafael Bruck is associated with Ramot University Authority for Applied Research and Industrial Development Limited, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on treating various non-malignant diseases.
Collaborations
Rafael has collaborated with esteemed colleagues, including Michael Jay Brownstein and Dimitrius Karussis. These collaborations have further enriched his research and contributed to the development of effective treatment methods.
Conclusion
Rafael Bruck's innovative work in the treatment of non-malignant diseases through the use of Ras antagonists showcases his commitment to advancing medical science. His contributions have the potential to significantly improve the lives of patients suffering from various conditions.